ArticleThe Korean journal of internal medicine2018

Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor.

Eunjung Yim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.